Experimental and human studies have shown that atrial fibrillation (AF) causes remodeling (1) (2) (3) (4) (5) (6) (7) (8) , that is, shortening of the refractory period and increase in spatial dispersion of refractoriness. Clinical and experimental studies have shown that the longer AF is allowed to exist, or remodeling is allowed to continue, the more difficult it becomes to obtain sinus rhythm (9) . Intracellular calcium overload has been suggested as the mechanism for remodeling. Recent reports have suggested that calcium entry blockers such as verapamil prevent remodeling (8, 10, 11) . However, all of these studies were carried out in models of recent-onset AF. In addition, despite extensive clinical experience with verapamil, antifibrillatory effects of verapamil have not become apparent. On the contrary, an earlier study by Shenasa et al. (12) showed that AF episode duration increased after verapamil administration. In addition, a recent experimental study by Lee et al. (13) showed that verapamil was useless in preventing remodeling in AF of longer duration. These authors also showed that verapamil increases atrial vulnerability and the duration of induced AF episodes. The present study was performed to assess the effect of verapamil on atrial fibrillation cycle length and spatial dispersion of refractoriness in patients with chronic AF.
METHODS
Patients. We studied 15 consecutive patients (average age 64.8 Ϯ 14.2 years, eight females) with chronic AF (duration of permanent AF Ͼ1 year). The underlying etiologies for AF were idiopathic (three patients), mitral valve disease (five patients), postinfarct (three patients), idiopathic dilated cardiomyopathy (two patients) and hypertension (two patients). The reason for electrophysiologic study was His bundle ablation for drug-refractory AF in 14 patients and diagnosis in one patient. All antiarrhythmic drugs had been discontinued for at least five half-lives and no patient was on amiodarone. All patients gave informed consent and the study was approved by the hospital ethical review board. Study protocol. Electrophysiologic study was performed in the fasting nonsedated state. Femoral venous access was obtained using local anesthesia. In all patients, a decapolar electrode catheter (interelectrode spacing 5 mm) was positioned against the right lateral free wall as described previously (14) . In the first eight patients, a quadripolar catheter was positioned in the right atrial appendage. In these patients, arterial pressure and right atrial pressure were continuously measured. In the final seven patients, the quadripolar catheter was positioned in the coronary sinus (CS) and a quadripolar Franz catheter (EPT, Sunnyvale, California) was used to record monophasic action potentials from the right atrial appendage. Twelve unipolar electrograms (filter 0.05 to 500 Hz) were recorded from the decapolar catheter and the two proximal electrodes from the quadripolar catheters (14) . The catheters were positioned to obtain a minimum of eight electrogram recordings with amplitude Ͼ0.5 mV. The atrial electrograms, surface leads (I, II, III, V 1 ), pressure tracings and monophasic action potentials were recorded using an electrophysiological system (Cardiolab, Prucka Engineering, Houston, Texas).
A 3-min period of AF was acquired. Verapamil (0.075 mg/kg) was then administered intravenously in 10 min. One minute after completion of verapamil infusion, another 3 min of fibrillatory electrograms were acquired. Data analysis. The technique used to measure fibrillatory intervals and to calculate spatial dispersion of refractoriness has been described previously (14) . Fibrillatory intervals were measured by detecting the intrinsic negative deflections. For each atrial recording site, histograms of fibrillatory intervals were plotted. Undersensing of intrinsic deflections was detected by observation of secondary peaks in the histogram. Such intervals were discarded (15) . The mean fibrillatory interval at each recording site was used as an index for local refractoriness (16) . Dispersion of refractoriness was measured by calculating the coefficient of dispersion. This was defined as the standard deviation of the mean of all mean local fibrillatory intervals expressed as a percentage of the overall mean fibrillatory interval (14) . Electrograms from the Franz catheter were used to measure monophasic action potential durations (APD 90 ) before and after verapamil administration (17) . Statistical analysis. At each individual recording site, fibrillatory intervals and APD 90 before and after verapamil were compared using Student t test. Pre-and postverapamil mean fibrillatory intervals, mean APD 90 , arterial and right atrial pressures for the total patient group were compared using a paired t test. Correlation coefficients between local fibrillatory interval and APD 90 were calculated both before and after verapamil. A p value of Յ0.05 was considered statistically significant.
RESULTS
In each patient, mean fibrillatory intervals significantly shortened at all individual atrial recording sites after verapamil ( Fig. 1 , Table 1 Table 2 . Decrease in mean fibrillatory intervals per recording site and a decrease in monophasic action potential duration in the right atrial appendage were highly significant. As shown in Figure 3 , there was a strong correlation between APD 90 and local mean fibrillatory interval both before and after verapamil administration (r ϭ 0.989; p Ͻ 0.001 and r ϭ 0.990; p Ͻ 0.001, respectively).
The relationship between APD 90 and local mean fibrillatory interval remained unchanged by verapamil. Dispersion of mean fibrillatory intervals in the right atrium increased significantly as shown in Table 1 . No significant differences were found between free wall, appendage and CS. Arterial pressure and right atrial pressure did not change significantly in any patient.
DISCUSSION
To our knowledge, this is the first study in patients with chronic AF to assess the acute effects of verapamil on AF cycle length and spatial dispersion of refractoriness. Verapamil caused a decrease in mean fibrillatory intervals and an increase in spatial dispersion. This study suggests that verapamil does not reverse remodeling in chronic atrial fibrillation. Finally, verapamil did not alter the linear relationship between AF cycle length and APD 90 , suggesting that verapamil does not alter the excitable gap during AF. Verapamil in atrial fibrillation. Atrial fibrillation is believed to produce electrophysiologic changes in the atrial myocardium, known as remodeling, which in turn facilitate the perpetuation of AF (1) (2) (3) (4) (5) (6) (7) (8) . This phenomenon has been attributed to intracellular calcium overload (8, 10, 11, 18) . Recent studies have suggested that verapamil prevents remodeling caused by pacing-induced AF (8, 10, 11) . All of these studies were performed in models of recent-onset AF. However, antifibrillatory effects of verapamil have not been demonstrated in a clinical setting.
In an earlier study Shenasa et al. (12) administered verapamil both intravenously and orally in a maintenance dose to patients for treatment of supraventricular tachycardia. The duration of electrically induced AF episodes significantly increased after both intravenous and oral verapamil administration. At the time of that study, this finding remained unexplained. In a recent study, Lee et al. (13) demonstrated that verapamil was unable to prevent remodeling after one and six weeks of pacing-induced AF in a canine model. In addition, verapamil increased the duration of induced AF episodes. Lee et al. (13) also showed that atrial conduction velocity remained unchanged by verapamil administration. The present study showed that verapamil caused shortening of atrial refractoriness in patients. Therefore, the wavelength of reentrant wavelets, being the product of conduction velocity and refractoriness, would also become shorter (1) . This would in turn promote AF perpetuation. This conclusion is supported by several studies that have demonstrated increased AF duration caused by shortened refractoriness (1, (5) (6) (7) (8) 10) . Thus, the verapamilinduced shortening of atrial refractoriness as found in our study may be the underlying mechanism of the increased AF duration.
Several studies reported increased atrial vulnerability after verapamil administration (19) . In a previous study by our group in patients without structural heart disease (14), dispersion of refractoriness was measured using the same catheter-based technique described in the present study. Atrial vulnerability was assessed using a staged stimulation protocol starting with single extrastimuli followed by more Mean fibrillatory intervals and APD 90 decreased in all patients at all recording sites. Dispersion at the right atrial free wall increased in all patients. There were no significant changes in arterial and right atrial pressure. AF ϭ atrial fibrillation; APD 90 ϭ monophasic action potential duration; CL ϭ cycle length; CS ϭ coronary sinus.
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Verapamil and Chronic Atrial Fibrillation aggressive pacing to induce AF. Increased dispersion of refractoriness was strongly associated with increased atrial vulnerability. An increase in dispersion of refractoriness as found in the present study after verapamil administration may explain the increased atrial vulnerability found in experimental studies. Methodological considerations. Mean fibrillatory intervals were used as an index for local refractory periods. This method, validated in previous studies (16, 17, 20, 21) , is the only practical technique to simultaneously evaluate changes of refractoriness at multiple sites in patients with chronic AF. Every patient provided his or her own control data for comparison with data obtained after verapamil administration. Some drugs such as procainamide, flecainide and ibutilide are known to alter the excitable gap during AF. After administration of such drugs, AF cycle length no longer correlates with APD 90 and local refractoriness (1, 17) . In our patients, however, a strong correlation was observed between AF cycle length and APD 90 both before and after verapamil administration, as shown in Figure 3 . Therefore the verapamil-induced decrease in fibrillatory cycle length would be more likely to be caused by a decrease in refractory period rather than a change in excitable gap.
Autonomic blockade was not used in the present study because beta-blockade in combination with verapamil was considered potentially hazardous for the studied patients. Verapamil effects may be mediated through a sympathetic response caused by verapamil-induced hypotension, as suggested by Friedman et al. (21) . These investigators administered a bolus of verapamil 0.2 mg/kg in an anesthetized canine preparation. This resulted in a decrease of arterial pressure and an increase in right atrial pressure, followed by enhanced sympathetic activity. These authors suggested that this increased sympathetic activity was solely responsible for the increased duration of AF episodes and the increased atrial vulnerability. In our patients, however, the verapamil dose was much lower (0.075 mg/kg) and was injected slowly in 10 min. Absence of significant changes in arterial or right atrial pressures suggested that intense sympathetic activity did not occur. In addition, Lee et al. (13) reported increased AF duration after verapamil during autonomic blockade with propranolol and atropine. These findings suggest that the mechanism of the increased duration of AF episodes in our study is not mediated by sympathetic reflex activity. Mechanistic implications. Several studies have provided evidence that intracellular calcium overload is the underlying mechanism of electrophysiologic remodeling Figure 3 . Mean fibrillatory interval and action potential duration (APD 90 ) were measured in the right atrial appendage in seven patients. For each of these patients, mean fibrillatory interval (x-axis) and APD 90 (y-axis) are plotted both before (black boxes) and after (white boxes) verapamil. Both mean fibrillatory intervals as well as APD 90 shortened significantly in each patient. The relationship between mean fibrillatory interval and APD 90 is linear both before and after verapamil administration, and the relationship between both parameters remains unchanged. Mean fibrillatory intervals decreased at all recording areas in all patients. APD 90 also decreased. RAA and CS were derived by averaging two recording sites. ⌬ indicates change (value after verapamil administration minus baseline value). APD 90 ϭ monophasic action potential duration derived from Franz catheter; CS ϭ coronary sinus; DC ϭ dispersion coefficient; RAA ϭ right atrial appendage; RFW ϭ right atrial free wall (mean fibrillatory interval derived by averaging eight to 10 recording sites from decapolar catheter).
